// App-Quantinova.ai

1082 : High-Risk Subtype of Ph-like Acute Lymphoblastic Leukemia (ALL) in Adults: Dismal Outcomes of CRLF2+ ALL Patients Treated with Intensive Chemotherapy

Researchers

Presenter

  • Nitin Jain

Principal Investigators

  • Elias J. Jabbour

  • I-Ming L. Chen

  • Debbie Payne-Turner

  • Marcus Valentine

  • Deborah A Thomas

  • Guillermo Garcia-Manero

  • Farhad Ravandi

  • Jorge E. Cortes

  • Steven M. Kornblau

  • Susan M. -Brien

  • Sherry Pierce

  • Keyur Patel

  • Jeffrey L. Jorgensen

  • Kenna Shaw

  • Cheryl L. Willman

  • Charles Mullighan

  • Hagop M. Kantarjian

  • Marina Konopleva

  • Karina Eterovic

  • Gloria Fawcett

  • Patrick Zweidler-McKay

  • Xinyan Lu

  • Sa Wang

  • Sergej Konoplev

  • Richard C Harvey

Medical Centers

  • Chao Family Comprehensive Cancer Center, University of California, Orange, CA

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • University of New Mexico Cancer Center, Albuquerque, NM

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • St. Jude Children's Research Hospital, Memphis, TN

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Institute of Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved